Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Cytokinetics, Incorporated (NASDAQ: CYTK)
CYTK Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
210.20%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
32.70%
CYTK Stock Analysis
CYTK
PE Ratio:
CYTK
PEG Ratio:
Not Available
CYTK
Forward EPS Growth (12 month):
0.00%
CYTK
PS Ratio:
83.2
CYTK
PSG Ratio:
0.3
CYTK
Forward Revenue Growth (12 month):
279.80%
CYTK Articles
No data was found